Remedium Bio were accepted into the P4precision medicine accelerator program
Posted:
Remedium Bio were accepted into the P4precision medicine accelerator program, a collaboration of UCL, London’s Global University, and Capital Enterprise, the UK’s largest startup ecosystem!
Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But, the Food and Drug Administration approved Kisqali in combination with hormone therapy for patients with certain early-stage breast cancers. …
Wearable technology that monitors our bodies can be helpful and harmful.
Wearable technology affords the opportunity to check, re-check, and check again, leading to fixation.
Read the full article in the Psychology Today blog post here.